| substance abuse | Maladaptive pattern of drug or alcohol use that may lead to social, occupational, psychological, or physical problems. (05 Mar 2000) |
|---|---|
| substance abuse detection | Detection of drugs that have been abused, overused, or misused, including legal and illegal drugs. Urine screening is the usual method of detection. (12 Dec 1998) |
| substance abuse disorders | A class of mental disorders in which behavioural and biological changes are associated with regular use of alcohol, drugs, and related substances that affect the central nervous system and personal and social functioning. (05 Mar 2000) |
| substance abuse, intravenous | Abuse, overuse, or misuse of a substance by its injection into a vein. (12 Dec 1998) |
| substance abuse treatment centres | Health facilities providing therapy and/or rehabilitation for substance-dependent individuals. Methadone distribution centres are included. (12 Dec 1998) |
| substance dependence | A pattern of behavioural, physiologic, and cognitive symptoms that develop due to substance use or abuse; usually indicated by tolerance to the effects of the substance and withdrawal symptoms that develop when use of the substance is terminated. (05 Mar 2000) |
| substance-induced organic mental disorders | Mental disorders caused by use of drugs, e.g., cocaine. (05 Mar 2000) |
| substance of lens of eye | That which constitutes the lens of the eye, composed of a nucleus and a cortex and covered by an epithelium. Synonym: substantia lentis. (05 Mar 2000) |
| substance P | A vasoactive intestinal peptide (1348 D) found in the brain, spinal ganglia and intestine of vertebrates. Induces vasodilatation, salivation and increases capillary permeability. Sequence: RPKPQFFGLM. (18 Nov 1997) |
| substance-related disorders | These non-psychotic disorders include those related to the taking of a drug of abuse (including alcohol), to the side effects of a medication, and to toxin exposure. (12 Dec 1998) |
| substance withdrawal syndrome | <syndrome> Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug. (12 Dec 1998) |
| innominate substance | The region of the forebrain that lies ventral to the anterior half or so of the lentiform nucleus, extending in the frontal plane from the lateral preopticohypothalamic zone laterally over the optic tract to the amygdala (amygdaloid body); rostrally it tapers off over the dorsal border of the olfactory tubercle, caudally it ends where the internal capsule reaches the surface to form the cerebral peduncle or pes pedunculi. Notable among its polymorphic cell population is the large-celled basal nucleus of Meynert. These magnocellular elements within the substantia i. Are present in the medial septum and the diagonal band of Broca, but occur in largest numbers ventral to the globus pallidus. Histochemical evidence indicates that magnocellular elements distribute cholinergic fibres widely in the cerebral cortex and that these cells undergo selective degeneration in Alzheimer's disease. Synonym: substantia innominata. (05 Mar 2000) |
| interspongioplastic substance | An obsolete term for cytochylema. (05 Mar 2000) |
| threshold substance | Any material (e.g., glucose) that is excreted in the urine only when its plasma concentration exceeds a certain value, termed its threshold. Synonym: threshold body. (05 Mar 2000) |
| tigroid substance | The material consisting of granular endoplasmic reticulum and ribosomes that occurs in nerve cell bodies and dendrites. Synonym: basophil substance, basophilic substance, chromophil substance, Nissl bodies, Nissl granules, substantia basophilia, tigroid bodies, tigroid substance. (05 Mar 2000) |